Header
Header
Article

With Pfizer deal, Global Blood sees chance to reach all sickle cell patients



The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live.

“When Albert called me, the first thing he said was, ‘You guys have really been amazing in what you’ve done in such a short period of time,’” said Ted Love, Global Blood’s CEO, recalling for me his conversation with Pfizer CEO Albert Bourla.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

Back to top button